Congestive Heart Failure Pipeline Market Research Report: Ken Research

0


Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure)-Pipeline Review, H1 2018, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. There are two types of heart failure including systolic heart failure (left ventricle loses its ability to contract normally) and diastolic heart failure (left ventricle loses its ability to relax normally). The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure)-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 14, 28, 19, 3, 49, 13 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 21 and 4 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Key Topics Covered in this Report:

  • Congestive Heart Failure Pipeline Market Research Report
  • Congestive Heart Failure Pipeline Market Industry Analysis
  • Congestive Heart Failure Pipeline Market Volume Sales
  • Congestive Heart Failure Pipeline Market Revenue
  • Congestive Heart Failure Pipeline Market Analysis
  • Congestive Heart Failure Pipeline Sector Forecast
  • Congestive Heart Failure Pipeline Industry Competition
  • Congestive Heart Failure Pipeline Industry Future Outlook
  • Congestive Heart Failure Pipeline Industry Trends

To know more, click on the link below:

https://www.kenresearch.com/healthcare/general-healthcare/congestive-heart-failure-pipeline-review/143894-91.html

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

0124-4230204

Share.

Comments are closed.